Analogue-based drug research: Lead and drug optimization

Medicinal Chemistry Research

Volumn 13, Issue 3-4, 2004, Pages 218-227

  Fischer, János ^a  

^a GEDEON RICHTER LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN II ANTAGONIST; AZATADINE; CANDESARTAN; CIGLITAZONE; CISAPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG ANALOG; EPROSARTAN; HISTAMINE H1 RECEPTOR ANTAGONIST; IRBESARTAN; KETOCONAZOLE; LOSARTAN; METOCLOPRAMIDE; MOSAPRIDE CITRATE; NARATRIPTAN; PIOGLITAZONE; PRACTOLOL; RIZATRIPTAN; ROSIGLITAZONE; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN 4 AGONIST; SUMATRIPTAN; TELMISARTAN; TERFENADINE; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN; ZOLMITRIPTAN;

ANGINA PECTORIS; CONFERENCE PAPER; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LIVER TOXICITY; MIGRAINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; QT PROLONGATION; STATISTICAL ANALYSIS; STRUCTURE ANALYSIS;

EID: 10644247676     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-004-0029-3     Document Type: Conference Paper

References (18)

1. IUPAC project "Analogue-based drug discovery" 2003 (www.iupac.org/projects).
2. IUPAC Recommendations: Glossary of terms used in the medicinal chemistry: Pure and Applied Chemistry 1998, 70, 1129.
3. Fischer, J.; Gere, A. Pharmazie 2001, 56, 675-682.
4. Furakawa, Y.; Kishimoto, S.; Nishikawa, K. (Takeda Chemical Industries Ltd.): 1982, U.S. Patents 4,340,598 and 4,355,040.
5. Carini, D.J.; Duncia, J.V.; Aldrich, P.E.; Chiu, A.T.; Johnson, A.L.; Pierce, M.E.; Price, W.A.; Santella III, J.J.B.; Wells, G.J.; Wexler, R.R.; Wong, P.C.; Yoo, S.-E.; Timmermanns, P.B.M.W.M. J. Med. Chem. 1991, 34, 2525, 1986, Eu.Patent 253,310
6. Sohda, T.; Mizuno, K.; Imamiya, E.; Suguyama, Y.; Fujita, T.; Kawamatsu, Y. Chem. Pharm. Bull 1982, 30, 3580.
7. Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Hasegawa, K.; Horikoshi, H. J. Med. Chem. 1989, 32, 421.
8. Warner-Lambert decided to discontinue marketing troglitazone for the treatment of type II diabetes due to the safety and efficacy reasons (Warner-Lambert News Release in Prous Science Daily Essentials, March 22, 2000).
9. Heuring, R.E.; Peroutka, S.J.J. Neurosci. 1987, 7, 894.
10. Sciberras, D.F.; Polvino, W.J.; Gertz, B.J.; Cheng, H.; Stepanavage, M.; Wittreich, J.; Olah, T.; Edwards, M.; Mant. T. Br. J. Clin. Pharmacol. 1997, 43, 49.
11. Fr. 1.313.758 (Soc. d'Etudes Scientifiques et Industrielles de l'Ille-de-France), 1961
12. MacDonald, T.M. Eur. J. Clin. Pharmacol. 1991, 40, 225
13. Craig, D.A.; Clarke, D.E.; J. Pharmacol. Exp. Ther. 1990, 252, 1378.
14. Yoshida, N.; Ito, T.; Karasawa, T.; Itoh, Z. J. Pharmacol. Exp. Ther. 1991, 257, 2572.
15. Barnett, A.; Green, M.J. "Chronicles of Drug Discovery" (Ed. Lednicer, D.) Vol. 3., ACS Professional Reference Book, Washington DC 1993 pp. 83-99.
16. Villani, F.J.; Wefer, E.A.; Mann, T.A.; Peer, L.; Levy, A.S. J. Heterocycl. Chem. 1972, 9, 1203.
17. Harting, J.; Becker, K.H.; Bergmann, R.; Bourgois, R.; Enenkel, H.J.; Fuchs, A.; Jonas, R.; Lettenbau, K.; Minck, K.O.; Schelling, P.; Schulze, E. Arzneim.-Forsch./Drug Res. 1986, 36, 200.
18. Erhardt, P.W. "Chronicles of Drug Discovery" Vol 3. Ed. Lednicer, D.)ACS Professional Reference Book, American Chemical Society, Washington DC, 1993, pp 191-206.